Frontier Biotechnologies Yönetim

Yönetim kriter kontrolleri 3/4

Frontier Biotechnologies CEO'su C. J. Wang, Jan2013 tarihinde atandı, in görev süresi 11.83 yıldır. şirketin hisselerinin 5.62% doğrudan sahiptir ve bu hisselerin değeri CN¥ 156.47M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 10.3 yıl ve 6.5 yıldır.

Anahtar bilgiler

C. J. Wang

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	11.8yrs
CEO sahipliği	5.6%
Yönetim ortalama görev süresi	10.3yrs
Yönetim Kurulu ortalama görev süresi	6.5yrs

Son yönetim güncellemeleri

Recent updates

CEO

C. J. Wang (66 yo)

11.8yrs

Görev süresi

CN¥2,228,000

Tazminat

Dr. Changjin Wang, also known as C. J., Ph D., serves as Chief Executive Officer and Director at Frontier Biotechnologies Inc. since January 2013. Dr. Wang served as Vice President of Business Development...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Qi Shao	Senior VP & CFO	8.8yrs	CN¥1.37m	Veri yok
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 161.6m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	no data	CN¥593.80k	Veri yok
Hangzhou Lv	Senior Vice President of Marketing & Sales	no data	CN¥1.22m	Veri yok
Qianya Gao	Deputy GM & Secretary of the Board of Directors	3.9yrs	CN¥962.00k	Veri yok
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 103.4m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 156.5m
Xiao Zheng	Chief Operating Officer	3.7yrs	CN¥3.47m	Veri yok
Michael Hu	C.M.O.	no data	Veri yok	Veri yok

10.3yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: 688221 'un yönetim ekibi deneyimli ve deneyimlidir ( 10.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rongjian Lu	CTO & Director	11.8yrs	CN¥1.88m	5.8% CN¥ 161.6m
Yuting Zhu	Supervisor & Deputy GM Administrative Director	5.8yrs	CN¥593.80k	Veri yok
Dong Xie	Founder	11.8yrs	CN¥2.26m	3.72% CN¥ 103.4m
Changjin Wang	MD, CEO & Director	11.8yrs	CN¥2.23m	5.62% CN¥ 156.5m
Chi Kit Ng	Independent Director	5.8yrs	CN¥150.00k	Veri yok
Yuantao Cao	Supervisor	6.5yrs	Veri yok	Veri yok
Guangji Wang	Independent Director	2.5yrs	CN¥130.20k	Veri yok
Kai Chen	Independent Director	5.8yrs	CN¥90.70k	Veri yok
Zhi Zhong Jiang	Chairman of the Supervisory Board & Purchasing Director	8.8yrs	CN¥380.60k	Veri yok

6.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 688221 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.5 yıldır).

Frontier Biotechnologies Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023)

Frontier Biotechnologies Inc. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.26 loss in 2Q 2023)

Frontier Biotechnologies Inc. to Report First Half, 2024 Results on Aug 31, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Frontier Biotechnologies Inc., Annual General Meeting, Apr 25, 2024

Frontier Biotechnologies Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: CN¥0.88 loss per share (vs CN¥0.98 loss in FY 2022)

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.29 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.18 loss in 2Q 2022)

Frontier Biotechnologies Inc. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.16 loss in 1Q 2022)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Frontier Biotechnologies Announces Positive Phase 1 Results of Its First Coronavirus Main Protease (Mpro) Small Molecule Inhibitor, Laying Foundation for the Treatment of Acute and Long COVID

Frontier Biotechnologies Inc. announced that it expects to receive CNY 270.2 million in funding from Jiezheng Investment Group Co., Ltd, UBS Group AG, Guodu Venture Capital Co., Ltd., Nuode Fund Management Co., Ltd., Guizhou Xiehui Property Development Company Limited

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to CN¥22.90

Full year 2021 earnings: EPS and revenues miss analyst expectations

Third quarter 2021 earnings released: CN¥0.23 loss per share (vs CN¥0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.23 loss in 2Q 2020)

Frontier Biotechnologies' First Long-Acting Injectable (Aikening(R)), in A Two Drug Regimen for HIV, Proves Safe and Efficacious for Patients

Full year 2020 earnings released: CN¥0.80 loss per share (vs CN¥0.73 loss in FY 2019)

New 90-day low: CN¥16.16

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş